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a b s t r a c t
Ocular exposure to inﬂuenza virus represents an alternate route of virus entry capable of establishing a
respiratory infection in mammals, but the effectiveness of currently available antiviral treatments to
limit virus replication within ocular tissue or inhibit virus spread from ocular sites to the respiratory
tract is poorly understood. Using an inoculation method that delivers an aerosol inoculum exclusively to
the ocular surface, we demonstrate that oral oseltamivir administration following ocular-only aerosol
inoculation with multiple avian and human inﬂuenza viruses protected ferrets from a fatal and systemic
infection, reduced clinical signs and symptoms of illness, and decreased virus transmissibility to
susceptible contacts when a respiratory infection was initiated. The presence of oseltamivir further
inhibited inﬂuenza virus replication in primary human corneal epithelial cells. These ﬁndings provide
critical experimental evidence supporting the use of neuraminidase inhibitors during outbreaks of
inﬂuenza virus resulting in ocular disease or following ocular exposure.
Published by Elsevier Inc.
Introduction
Inﬂuenza virus is a highly contagious respiratory pathogen;
high viral loads are expelled during coughing and sneezing of
infected individuals, and inhalation of virus-containing aerosols by
susceptible contacts represents a principal route of human infec-
tion (Milton et al., 2013; Tellier, 2009). However, like many
respiratory pathogens, ocular exposure to inﬂuenza viruses con-
stitutes a secondary route of virus entry, with the eye representing
both a potential site of virus replication as well as a portal for
establishing a respiratory infection (Belser et al., 2013b). While H7
subtype inﬂuenza viruses have typically been associated with
ocular exposure and disease in humans, reports of both avian
and human inﬂuenza viruses causing conjunctivitis have been
documented (Belser et al., 2013b). Furthermore, ocular inocul-
ation of mammalian models has demonstrated the ability of select
inﬂuenza viruses to cause a fatal infection following ocular
exposure, or to maintain a transmissible phenotype following
ocular exposure, even in the absence of an ocular tropism
(Belser et al., 2014, 2012a). Still, ocular exposure remains a poorly
understood route of viral entry, limiting our ability to study
effective treatment options in humans exposed to inﬂuenza
viruses by the ocular route or presenting with ocular symptoms.
Neuraminidase (NA) inhibitors represent the most widely used
class of antiviral drug to treat individuals presenting with respira-
tory symptoms of inﬂuenza virus infection (Ison, 2015). Early
administration of the NA inhibitor oseltamivir is associated with
reduced clinical signs and symptoms of infection and reduced viral
loads in respiratory tract tissues; oseltamivir prophylaxis is fre-
quently prescribed during outbreaks of avian inﬂuenza virus
where there is a risk of occupational exposure to the virus
(Koopmans et al., 2004; Writing Committee of the Second World
Health Organization Consultation on Clinical Aspects of Human
Infection et al., 2008). Despite a paucity of experimental evidence
examining the efﬁcacy of antiviral treatments following infection
by non-respiratory exposure routes, oseltamivir treatment and
prophylaxis has nonetheless been prescribed during outbreaks in
humans where conjunctivitis and/or ocular exposure has been
reported (Koopmans et al., 2004; Tweed et al., 2004). Oral
oseltamivir treatment has been shown to reduce viral patho-
genesis and limit virus transmissibility in numerous mamm-
alian models following inoculation with inﬂuenza viruses, though
these studies have been limited to respiratory inoculation routes
(Govorkova et al., 2007; Govorkova et al., 2011; Watanabe et al.,
2013). As there are no antiviral drugs to treat viral conjunctivitis
caused by respiratory viruses, it is necessary to assess the efﬁcacy
of currently available treatments to reduce viral replication in
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non-respiratory tissues such as the eye, in addition to examining
drug efﬁcacy when infection is initiated following virus exposure
by non-respiratory routes.
A previous study from our laboratory demonstrated that
oseltamivir inhibits H7 inﬂuenza virus replication in mice inocu-
lated by the ocular route, with reductions in morbidity, mortality,
and viral titers in both respiratory and ocular tissues in antiviral-
treated mice (Belser et al., 2012b). However, there remains a need
to better understand the capacity of currently available antiviral
treatments to both inhibit virus spread from ocular sites to the
respiratory tract and mitigate ocular disease caused by inﬂuenza
virus infection. Here, we used a novel method of ocular-only
aerosol (OA) inoculation of ferrets to investigate the ability of
oseltamivir to prevent inﬂuenza virus infection, disease progres-
sion, and transmissibility following ocular exposure to inﬂuenza
virus. We demonstrate that oral oseltamivir treatment effectively
limits the establishment of a respiratory infection in ferrets
exposed to aerosolized inﬂuenza virus by the ocular-only route,
and reduces the transmission of viruses of multiple subtypes to
naïve contacts when a respiratory infection results from ocular
inoculation. Furthermore, we show that oseltamivir can limit
inﬂuenza virus replication in human corneal epithelial cells.
Results
Efﬁcacy of oseltamivir administration following OA inoculation with
H5N1 virus
Oseltamivir treatment has been shown to reduce morbidity,
mortality, and systemic spread of HPAI H5N1 viruses in ferrets
inoculated by the traditional intranasal route (Boltz et al., 2008;
Govorkova et al., 2007), but not following inﬂuenza virus infection
by alternate exposure routes. As previous work found that the HPAI
H5N1 virus A/Thailand/16/2004 (Thai/16) was lethal to ferrets follow-
ing ocular inoculation (Belser et al., 2014, 2012a), ferrets inoculated by
the OA route with Thai/16 virus were orally administered 25mg/kg of
body weight/day of oseltamivir phosphate, or distilled water as a
control, from 2 h p.i. through day 5 p.i. Both treated and control ferrets
were monitored daily for clinical signs of illness, and nasal wash (NW),
conjunctival wash (CW), and rectal swabs (RS) were collected on
alternate days to assess virus replication.
Ferrets administered oseltamivir survived the H5N1 viral challenge,
with transient weight loss and fever the only clinical signs and
symptoms detected in this group (Table 1). While infectious virus
was not detected in NW, CW, or RS samples during the acute phase of
infection (Table 1, Fig. 1A), all treated ferrets seroconverted by day 21
p.i. (data not shown). In contrast, untreated ferrets inoculated by the
OA route with the H5N1 virus succumbed to infection on days 5–7 p.i.,
presenting with weight loss, sustained fevers, nasal discharge,
diarrhea, and neurological signs (Table 1). Virus was only detected
sporadically and at low titer in NW (o200 PFU/mL), CW (o50 PFU/
mL), and RS (o600 PFU/mL) samples prior to euthanasia. However,
postmortem necropsy revealed extensive systemic spread of virus in
all untreated ferrets, including the respiratory tract, ocular tissue,
and brain (Fig. 1B), with viral loads generally comparable to ferrets
administered high doses of Thai/16 virus by the traditional intranasal
route (Maines et al., 2005). In summary, we found that oseltamivir
administration following OA inoculation with a HPAI H5N1 virus
protected ferrets from a fatal, systemic infection.
Reduced virus transmissibility in ferrets receiving oseltamivir
following OA inoculation
To examine a diverse range of viruses to which humans could
potentially be exposed, we next challenged ferrets by the OA route
with two inﬂuenza A viruses recently associated with human
infection: the HPAI H7N3 virus A/Mexico/InDRE7218/2012 (Mex/
7218) isolated from a poultry worker with conjunctivitis (Lopez-
Martinez et al., 2013), and a representative 2009 H1N1 pandemic
virus A/Mexico/4482/2009 (Mex/4482) isolated from a patient
with severe respiratory disease (Maines et al., 2009). Both viruses
have been shown previously to cause a moderate infection in
ferrets following inoculation by the OA (Mex/7218) or aerosol
inhalation (AR) route (Mex/4482), and are capable of transmission
in a ferret direct contact model (Belser et al., 2013a; Gustin et al.,
2013). The efﬁcacy of oseltamivir treatment to reduce virus
virulence and transmissibility was examined for both viruses.
Similar to inoculation with Thai/16 virus, ferrets treated with
oseltamivir and inoculated with the HPAI H7N3 virus Mex/7218
did not shed infectious virus in NW samples, whereas virus was
detected in NW samples from both untreated ferrets (Fig. 2A).
Moreover, oseltamivir treatment of Mex/7218-inoculated ferrets
was associated with reduced maximum weight loss (0–3%) com-
pared with untreated ferrets (7.3–12.3%) (Table 1). Seroconversion
to homologous virus was detected in two of three oseltamivir-
treated ferrets and all untreated ferrets (data not shown). Trans-
mission of virus to naïve cagemates was not detected in
oseltamivir-treated ferrets (all contact ferrets remained
Fig. 1. Oseltamivir efﬁcacy following OA inoculation of ferrets with HPAI H5N1
virus. Ferrets were inoculated by the OA route with Thai/16 virus at the doses
reported in Table 1 and administered oseltamivir phosphate or distilled water as a
control (n¼3 per group). (A), viral titers in nasal wash specimens were determined
on the indicated days p.i. (B), tissues collected from control-treated ferrets
euthanized due to neurological symptoms days 5–7 p.i. were titered for presence
of infectious virus by standard plaque assay. NT, nasal turbinates; Tr, trachea; Lg,
lung; BnOB, olfactory bulb; BnAnt, anterior brain; BnPos, posterior brain; Conj,
conjunctiva; Lv, liver; Kd, kidney; Sp, spleen; Int, pooled intestine; Bd, blood. Bars
represent individual ferrets. Limit of detection was 10 PFU/ml or g.
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seronegative at day 21 p.c.), while one of two untreated ferrets
transmitted virus in the presence of direct contact (seroconversion
was not detected in the ferret for which infectious virus was not
recovered).
Oseltamivir treatment of ferrets inoculated by the OA route
with Mex/4482 virus resulted in fewer ferrets shedding infectious
virus in NW samples (1/3), reduced maximum weight loss (1.6–
3.9%), and the absence of virus detected in naïve ferrets co-housed
with inoculated animals (Table 1, Fig. 2B), compared with
untreated ferrets, all of which shed virus in NW samples, exhibited
greater maximum weight loss (5.8–13.7%), and transmitted virus
to naïve ferrets (Table 1, Fig. 2B). Among naïve ferrets co-housed
with oseltamivir-treated ferrets, only one ferret exhibited sero-
conversion to Mex/4482 virus (the cagemate to the inoculated
ferret with positive NW detection), with no seroconversion
detected in other contact ferrets (Fig. 2B and data not shown).
These results show that oseltamivir treatment can lead to dimin-
ished pathogenicity and transmissibility of numerous virus sub-
types following OA exposure.
Efﬁcacy of oseltamivir following joint ocular-respiratory aerosol
exposure of ferrets
In the absence of either respiratory or ocular protection, a joint
ocular-respiratory exposure represents a probable exposure event
for individuals in community settings. To more closely mimic a
‘natural’ human exposure, we exposed ferrets to aerosolized LPAI
H7N9 A/Anhui/1/2013 (Anhui/1) inﬂuenza virus by the OA route
with or without concurrent low-level (1.2–11 PFU) AR exposure
(Table 1, Fig. 3A and B). Control ferrets received an ocular-only
exposure to virus (Fig. 3C). The virus Anhui/1, isolated from a fatal
case at the beginning of the H7N9 outbreak in 2013, represents a
current public health threat for which both respiratory and ocular
exposure of humans is possible (Gao et al., 2013).
Unlike H5N1, H7N3, or H1N1 OA challenges, virus was detected
in NW specimens of all oseltamivir-treated ferrets infected with
H7N9 virus by either OA only or joint OA-AR exposure (Fig. 3A and
B). Clinical signs and symptoms were generally comparable
between oseltamivir-treated and untreated ferrets, and all inocu-
lated ferrets mounted a respiratory infection (Table 1). Untreated
ferrets inoculated with Anhui/1 virus efﬁciently transmitted virus
to 100% of cagemates when placed in direct contact, with virus
detected in NW specimens from all animals by day 3 p.c. (Fig. 3C).
In contrast, transmission among ferrets exposed to Anhui/1 virus
by the OA route or OA-AR route and treated with oseltamivir was
less efﬁcient, with transmission was detected in 2/2 and 2/4 ferret
pairs, respectively (Fig. 3A and B). Compared with control ferrets,
transmission events were delayed (with onset of virus detection in
contact ferrets day 9 p.c.) or resulted in reduced replication in
contacts (with peak titers in NW specimens from contact ferrets
o200 PFU/mL). In summary, we found that oseltamivir treatment
limited the establishment of a transmissible respiratory infection
in ferrets exposed to aerosolized LPAI H7N9 inﬂuenza virus by
both ocular and joint ocular-respiratory routes.
Inhibitory activity of oseltamivir carboxylate in human respiratory
and ocular cells
While our results in the ferret model agree with previous
work demonstrating reduced viral loads in ocular tissue of
Fig. 2. Reduced inﬂuenza virus transmissibility in ferrets receiving oseltamivir following OA inoculation. Ferrets were inoculated by the OA route with Mex/7218 virus (A) or
Mex/4482 virus (B) at the doses reported in Table 1 and administered oseltamivir phosphate (left column) or distilled water as a control (right column). A naïve ferret was
placed in the same cage as each inoculated ferret at 24 h p.i. in order to assess virus transmission in the presence of direct contact. Nasal washes were collected from
inoculated and contact ferrets on alternate days p.i. (solid bars) or p.c. (hatched bars). The limit of virus detection was 10 PFU/mL.
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oseltamivir-treated mice (Belser et al., 2012b), the efﬁcacy of
oseltamivir speciﬁcally within human ocular tissue has not
been studied. We examined the susceptibility of inﬂuenza
viruses to oseltamivir carboxylate in primary human corneal
epithelial cells (HCEpiC) and compared with the human bron-
chial epithelial cell line Calu-3 and MDCK cells. All cell types
have been shown previously to support productive replication
of human and avian inﬂuenza viruses (Belser et al., 2011b).
Cells were infected with inﬂuenza viruses at a MOI of 0.001,
and cultured in the presence of serially diluted non-cytotoxic
quantities of oseltamivir carboxylate to determine reductions
of virus yield.
All inﬂuenza viruses tested demonstrated sensitivity to oselta-
mivir carboxylate in all cell types examined. Treatment with
100 mm of oseltamivir carboxylate limited viral titers of H7N3,
H7N9, and H1N1 viruses to o102 PFU/ml at 24 h and o103.3 PFU/
ml at 48 h p.i (Fig. 4). At this concentration of drug, viral titers of
the HPAI H5N1 virus Thai/16 were reduced by 4.3–5.8 logs
compared with control-treated cultures at 24 h p.i. While the
reductions in viral yield observed following oseltamivir carbox-
ylate treatment varied between cell types in a strain-speciﬁc
manner, with greater fold reductions in titer observed for viruses
that replicated robustly in the absence of oseltamivir, dose-
dependent inhibition was observed for all viruses tested regardless
of replication efﬁciency. Comparable results were observed at a
MOI of 0.01 (data not shown). These results indicate that, similar
to human respiratory tract cells, treatment of human ocular cells
with oseltamivir carboxylate effectively inhibits viral yields early
after infection.
Discussion
Neuraminidase inhibitors are frequently employed to limit
inﬂuenza virus infection and spread following respiratory expo-
sure. Understanding how inoculation route and inoculation dose
modulate the resulting severity of disease in humans has obvious
implications for clinical treatment and mitigation of transmission
to susceptible contacts. As the eye represents a secondary mucosal
surface bearing permissive viral receptors, located proximal to the
nasal passages and as such likely co-exposed during respiratory
inhalation of virus, we chose ocular inoculation as a model non-
respiratory inoculation route to study this property (Belser et al.,
2013b). The utility of the ferret model to study viral conjunctivitis
has been previously reported (Kirkeby et al., 2013); while inﬂu-
enza virus-infected ferrets do not typically display macroscopic
ocular disease, the close physiologic relatedness between ferrets
and humans warrants the use of this species to study ocular
exposure and the efﬁcacy of antiviral treatment following infec-
tion (Belser et al., 2011a).
Ocular inoculation of inﬂuenza viruses in mammalian models
typically leads to delays and/or reductions in symptom onset and
virus detection compared with traditional intranasal inoculation
(Aamir et al., 2009; Belser et al., 2014, 2012a, 2009; Sun et al.,
2009). Despite differential kinetics between inoculation routes,
oseltamivir treatment administered orally for the standard 5 days
p.i. was sufﬁcient to abrogate detectable virus replication in the
upper respiratory tract of treated ferrets with two HPAI viruses
(Figs. 1 and 2), and further limit the establishment of a respiratory
infection in ferrets exposed to aerosolized LPAI or 2009 pandemic
inﬂuenza virus by the OA route. Each virus is processed differently
during aerosolization; while challenge doses varied between
viruses used in this study, inoculating doses of all ferrets for each
virus were generally equivalent (within one log) (Table 1). Of note,
the 2009 H1N1 virus Mex/4482 is highly infectious, with low
inoculating doses (o1 PFU of total OA exposure) sufﬁcient to
mount a productive respiratory infection in untreated ferrets
(Table 1). This low inoculating dose was necessary to demonstrate
oseltamivir efﬁcacy as inoculation with high doses of this virus has
been shown previously to limit abrogation of virus in NW speci-
mens from drug-treated ferrets (Govorkova et al., 2011; Marriott et
al., 2014). In accord, while viral titers in Anhui/1 OA and OA-AR
virus-challenged ferrets were reduced and delayed compared with
control ferrets, the sustained detection of virus in NW specimens
from these groups may in part be due to the relatively higher
inoculating dose use in this challenge (4100 PFU) (Table 1).
Fig. 3. Reduced H7N9 virus transmissibility in oseltamivir-treated ferrets receiving
ocular-only or joint ocular-respiratory exposure. Oseltamivir-treated ferrets were
inoculated by the OA route without (A) or with (B) respiratory (AR) exposure to
Anhui/1 virus at the doses reported in Table 1, or inoculated by the OA route
without respiratory exposure and administered distilled water as a control (C). A
naïve ferret was placed in the same cage as each inoculated ferret at 24 h p.i. in
order to assess virus transmission in the presence of direct contact. Nasal washes
were collected from inoculated and contact ferrets on alternate days p.i. (solid bars)
or p.c. (hatched bars). The limit of virus detection was 10 PFU/mL.
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Human cases of inﬂuenza resulting from a known ocular
exposure are typically self-limiting, though documented instances
of probable person-to-person transmission have been reported
(Koopmans et al., 2004). Furthermore, viruses not typically asso-
ciated with an ocular tropism, such as the 2009 H1N1 pandemic
virus, have nonetheless been found capable to cause ocular
symptoms in infected individuals (Mansour et al., 2012). Thus,
our ﬁnding that oseltamivir treatment following ocular exposure
reduces virus transmission to naïve contacts when a respiratory
infection is established supports the use of antiviral treatments in
outbreak settings where ocular symptoms such as conjunctivitis
are the primary manifestation of disease. Comparable results
between ferrets receiving an ocular-only aerosol dose of Anhui/1
virus and those receiving a concurrent ocular and low-level (10
PFU) respiratory exposure demonstrates the utility of antiviral
treatment following a more rigorous virus exposure (Fig. 3). This is
of particular note as select avian inﬂuenza viruses have caused
concurrent ocular and respiratory disease (Avian inﬂuenza, 2007;
Tam, 2002; Tweed et al., 2004; Writing Committee of the Second
World Health Organization Consultation on Clinical Aspects of
Fig. 4. Reduction of inﬂuenza virus yield by oseltamivir carboxylate in multiple cell types. MDCK (A), Calu-3 (B), or HCEpiC (C) cells were infected with H5N1, H7N9, H7N3, or
H1N1 viruses at a MOI of 0.001 and cultured p.i. with medium containing the indicated quantity of oseltamivir carboxylate. 24 h (left column) or 48 h (right column) p.i.,
culture supernatant was sampled and titered for the presence of infectious virus by plaque assay. Values represent the meanþstandard deviation for triplicate wells; limit of
detection was 10 PFU/mL.
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Human Infection et al., 2008), and in the absence of personal
protective equipment, simultaneous exposure of both respiratory
and ocular tissues is likely. Our results further suggest that
oseltamivir prophylaxis of naïve cagemates would offer compar-
able levels of protection as has been observed following traditional
intranasal inoculation of ferrets (Oh et al., 2014). Previous work in
the ferret model has demonstrated that oral administration of
oseltamivir does not typically generate drug-resistant variants
during the acute phase of infection (Govorkova et al., 2007,
2011); nonetheless, future studies examining ocular exposure to
oseltamivir-resistant inﬂuenza viruses and the role of oseltamivir
drug-resistance in the context of ocular infection is warranted.
The human eye and surrounding conjunctiva possess numerous
discrete cell types which are permissive to inﬂuenza virus infection
(Belser et al., 2011b; Chan et al., 2010; Michaelis et al., 2009). While
the mechanisms underlying viral conjunctivitis associated with H7
subtype viruses are poorly understood, high viral loads leading to
increased inﬂammation in ocular tissue may represent a contribut-
ing factor (Chan et al., 2010). The majority of antiviral drugs
available to treat viral conjunctivitis are targeted towards herpes-
virus and adenovirus infection; ocular disease caused by RNA
viruses such as inﬂuenza or RSV currently lack commercially
available antiviral drug treatments (Skevaki et al., 2011). The high
bioavailability of oseltamivir following oral administration (Davies,
2010; Wattanagoon et al., 2009) likely contributes to the reduced
viral titers observed in ocular tissue following ocular inoculation of
either mice or ferrets with inﬂuenza viruses (Belser et al., 2012b).
Our ﬁnding that oseltamivir reduces inﬂuenza virus titers in human
ocular cells in a dose-dependent manner is in agreement with these
studies (Fig. 4).
Inﬂuenza virus pathogenicity and transmissibility in mammals
represent multifactorial traits, with numerous host and viral
factors contributing to disease severity. Recent advances in mam-
malian modeling of inﬂuenza viruses have illustrated that expo-
sure route and dose can similarly inﬂuence the presentation of
clinical signs and symptoms of disease (Gustin et al., 2012).
Accordingly, prevention and control measures must be evaluated
in settings which reﬂect the heterogeneity intrinsic in human
exposure. While this study examined ocular-only virus exposure,
using ﬁxed concentrations of virus for each ferret challenge and a
ﬁxed exposure time, further modulation and characterization of
inoculation parameters in mammalian models will allow for both a
broader understanding of the inherent variability in inﬂuenza
virus virulence as well as provide greater guidance in the devel-
opment, assessment, and use of anti-inﬂuenza stratagems.
Methods
Viruses
Inﬂuenza A viruses used in this study are shown in Table 1.
Virus stocks were propagated in the allantoic cavity of 10-day-old
embryonated hens' eggs (Maines et al., 2005), and virus stock
titers were determined by standard plaque assay using Madin-
Darby canine kidney cells (MDCK) (ATCC, Manassas, VA) (Zeng et
al., 2007). All experiments were conducted under biosafety level
3 containment, including enhancements as required by the U.S.
Department of Agriculture and the National Select Agent Program
(Chosewood and Wilson, 2009).
Table 1
Infectivity and pathogenesis of inﬂuenza A viruses in ferrets inoculated by the ocular aerosol route and given antiviral treatment.
Virus Subtype Tamiﬂua Ocular doseb Resp dosec Clinical signs Virus detection
Wt lossd Fevere Lethalityf NWg CWg RSg
Thai/16 H5N1 Yes 28–88 o1 7.2 (4–10) 1.5 0/3 0/3 0/3 0/3
No 34–60 o1 9.4 (5–7) 2.3 3/3 (5–7) 1/3 1/3 2/3
Mex/7218 H7N3 Yes 15–216 o1 2.0 (4–8) 2/3 1.4 0/3 0/3 0/3 0/3
No 94–114h o1 9.8 (11–12) 1.8 0/2 2/2 1/2 0/2
Mex/4482 H1N1 Yes 0.08–0.44 o1 2.9 (6–8) none (0/3) 0/3 1/3 0/3 0/3
No 0.36–0.84 o1 11.0 (9 -1 2) 1.2 0/3 3/3 1/3 0/3
Anhui/1 H7N9 Yes 214–520h o1 6.8 (10) 1/2 1.4 (1/2) 0/2 2/2 0/2 0/2
Yes 116–840 1.2–11 5.8 (2–12) 3/4 1.7 (3/4) 0/4 4/4 0/4 0/4
No 780–1220 o1 4.3 (8–10) 2.1 0/4 4/4 1/4 2/4
a Ferrets received 25 mg/kg of body weight/day oseltamivir phosphate given orally twice daily from 2 h p.i. through day 5 p.i. or control (distilled water).
b Presented ocular dose (expressed in PFU) is calculated as the virus concentration in the aerosol passed over the ocular surface multiplied by the exposure time (20 min
for all viruses with the exception of Thai/16 at 10 min).
c Estimation of presented respiratory dose (expressed in PFU) is calculated as the virus concentration in the aerosol present in the secondary holding chamber multiplied
by the exposure time. Ferrets with a respiratory dose o1 PFU were considered to be inoculated by the ocular-only aerosol route.
d Mean maximum weight loss, expressed as a percentage, among ferrets with detectable weight loss (with the day range p.i. of peak weight loss given in parentheses).
The number of ferrets with detectable weight loss/total number of ferrets in group is reported when not all ferrets presented with this clinical sign.
e Mean maximum rise in body temperature, in degrees centigrade, among ferrets with fevers (the number of ferrets with fevers/total number of ferrets in group is
reported in parentheses when not all ferrets presented with this clinical sign). The baseline temperature range was 37–39 1C. Fever was deﬁned as a rise of 41 1C from
baseline.
f Number of ferrets that succumbed to infection or were euthanized due to severe illness/total number of ferrets tested (with the days of death p.i. given in
parentheses).
g Number of ferrets with positive virus detection in nasal wash (NW), conjunctival wash (CW), or rectal swabs (RS)/total number of ferrets. Limit of virus detection was
10 PFU/ml.
h An additional ferret received an ocular dose of 300 PFU (Anhui/1) or 110 PFU (Mex/7218) but did not shed virus in NW specimens and did not seroconvert; each is
excluded from this analysis.
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Inoculation and assessment of drug efﬁcacy in ferrets
Male Fitch ferrets (Triple F Farms) were 6-to-8 months old and
serologically negative by hemagglutination inhibition assay to
currently circulating inﬂuenza viruses (H1N1 [2009 pandemic],
H3N2 [A/Perth/16/2009], and B [Yamagata and Victoria lineages].
Ferrets were housed in a Duo-Flo Bioclean mobile environmental
enclosure (Lab Products, Seaford, DE) for the duration of each
experiment. Ocular-only aerosol (OA) inoculation of ferrets were
performed by passing aerosolized virus through aerosol-delivery
goggles ﬁtted on sedated ferrets (Belser et al., 2014). The ocular
dose presented to each ferret was calculated by multiplying the
concentration of virus in the aerosol by the exposure time; all
ferrets inoculated by the OA-only route received o1 PFU of
respiratory exposure. Ferrets which received Z1 PFU of respira-
tory exposure (measured by sampling the air inside the secondary
animal holding chamber) were either excluded from the study or
studied for joint ocular-respiratory exposure (Table 1). Ferrets
received control (distilled, sterile water) or 25 mg/kg of body
weight/day oseltamivir phosphate (Sequoia Research Products,
United Kingdom) suspended in 15% fructose orally twice daily
(12.5 mg/kg per dose) from 2 h post-inoculation (p.i.) through
day 5 p.i.
Ferrets were monitored daily for morbidity and clinical signs of
infection for 14 days p.i. (Maines et al., 2005). Any ferret which
lost 425% of its preinoculation body weight or exhibited neuro-
logical dysfunction was euthanized and submitted to postmortem
examination. Virus shedding was measured in nasal wash, con-
junctival wash, and rectal swab samples (Belser et al., 2012a).
Naïve ferrets were placed in the same cage as inoculated ferrets to
measure virus transmission in the presence of direct contact, with
serum collected 17-to-23 days p.i./post-contact (p.c.) to measure
seroconversion by hemagglutinin inhibition (Maines et al., 2006).
Animal research was conducted in an Association for Assessment
and Accreditation of Laboratory Animal Care International-
accredited facility, under the guidance of the CDC's Institutional
Animal Care and Use Committee.
Cell culture and viral infection
The bronchial epithelial cell line Calu-3 (ATCC) was cultured on 6-
well membrane inserts (Zeng et al., 2007). Primary human corneal
epithelial cells (HCEpiC, ATCC) were grown to conﬂuence in 12-well
plates in serum-free medium. MDCK cells were grown to conﬂuence
in 6-well plates. Virus was added apically at a multiplicity of infection
(MOI) of 0.01 or 0.001 for one hour before washing. To assess
reduction of inﬂuenza virus yields by oseltamivir carboxylate in each
cell type, cell type-speciﬁc serum-free media containing indicated
concentrations (0–100 mM) of oseltamivir carboxylate (Sequoia) was
added to the cultures (Ilyushina et al., 2006), with the addition of
300 mg/liter N-p-tosyl-ʟ-phenylalanine chloromethyl ketone (TPCK-
trypsin) in HCEpiC and MDCK cultures. Aliquots of apical culture
supernatants were harvested at indicated times p.i. and titered for the
presence of infectious virus by standard plaque assay.
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